Twice-Yearly shot for HIV prevention put to the test in major US study
Prevention
Not yet recruiting
This study aims to see how well people in real-world clinics stick with a long-acting injectable drug called lenacapavir to prevent HIV. It will follow 3000 people across the United States for up to two years to understand how they start, use, and sometimes stop this prevention m…
Sponsor: Gilead Sciences • Aim: Prevention
Last updated Mar 24, 2026 12:02 UTC